In randomized clinical trials in which basal insulin dose was titrated seeking a predefined self-monitored plasma glucose target, this translated into less hypoglycemia [10, 11, 12, 13, 14, 15, 16] and apparently lower glycemic fluctuation with the same efficacy in terms of HbA1c reduction [17]. This evidence concerns the gene INS and Hypoglycemia.